期刊文献+

前列倍喜胶囊联合非那雄胺治疗糖尿病合并良性前列腺增生症疗效观察 被引量:10

原文传递
导出
摘要 目的:观察前列倍喜胶囊联合保列治对患有良性前列腺增生症( BPH)糖尿病患者的临床疗效。方法将符合标准的糖尿病合并BPH患者78例,按治疗方法不同分为治疗组(40例)和对照组(38例)。在基础治疗的同时,治疗组予非那雄胺及前列倍喜胶囊;对照组只予以非那雄胺治疗。对两组患者的国际前列腺症状评分( IPSS)、最大尿流率( Qmax)、生活质量评分( QOL)及前列腺体积( BV)和膀胱残余尿量进行观察。结果两组治疗后IPSS分均有所下降,差异有统计学意义( P <0.01),其中治疗组较对照组下降更加明显( P <0.01);两组治疗后Qmax均有所改善,差异有统计学意义( P <0.01或P <0.05),其中治疗组较对照组下降更加明显( P <0.05);两组治疗后QOL评分均有所提高,差异有统计学意义( P <0.05)。两组治疗后前列腺体积均较治疗前明显缩小,差异有统计学意义( P <0.05);两组治疗后膀胱残余尿量均明显减少,差异有统计学意义( P <0.05)。治疗过程中未见明显的不良反应。结论前列倍喜胶囊与非那雄胺片联合应用能明显降低BPH患者IPSS评分,改善QOL评分,提高Qmax,同时减少膀胱残余尿量,缩小前列腺体积,疗效优于单独使用非那雄胺片组。
出处 《中国医师杂志》 CAS 2015年第3期431-433,共3页 Journal of Chinese Physician
  • 相关文献

参考文献14

  • 1孟宪琴,刘伟,屈晓冰,杜万红,刘颖.糖尿病与良性前列腺增生的相关性研究[J].中国全科医学,2013,16(30):3547-3550. 被引量:17
  • 2Qu x, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients [ J]. Int Urol Nephrol,2014,46(3 ) :499-504.
  • 3Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower uri- nary tract symptoms in a population-based sample of African-Amer- ican men [ J ]. Am J Epidemio1.2003.157 ( 10 ) : 906 -914.
  • 4中华医学会糖尿病学分会.2013年版中国糖尿病防治指南[M].北京:北京大学医学出版社,2014:8-9.
  • 5Parsons JK, Carter HB, Partin AW, et al. Metabolic factors asso- ciated with benign prostatic hyperplasia [ J ]. J Clin Endocrinol Metab, 2006,91 ( 7 ) : 2562 -2568.
  • 6Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyper- plasia [ J ]. Prostate Cancer Prostatic Dis, 2009,12 ( 2 ) : 160 - 165.
  • 7Kim WT, Yun SJ, Choi YD, et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels[J]. J Korean Med Sci, 2011,26(9) :1214-1218.
  • 8Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia: the connection [ J ]. Eur J Pharmacol, 2010,641 (2-3) :75-81.
  • 9褚琳,陈陵霞,苗懿德,刘杰,宝辉,魏雅楠,郏蓉,苏琳,张庆文,李卫.2型糖尿病患者血糖控制与良性前列腺增生的相关性研究[J].中国全科医学,2013,16(23):2671-2673. 被引量:10
  • 10Roehrbom CG, Boyle P, Bergner D, et al. Serum prostate-spe- cific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trim comparing finasteride versus placebo. PLESS Study Group[J]. Urology, 1999,54 (4) :662-669.

二级参考文献59

  • 1Aggarwal S,Thareja S,Verma A,et al.An overview on 5al-pha-reductase inhibitors[J].Steroids,2010,75(2):109-153.
  • 2吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591.
  • 3Rowhrborm CG, McConnell JD. Etiology, pathothysiology. epidemiologyand natural history of binign prostatic hyperplasia. In: Walsh PC, Retik AB,Vaughan ED, eds. Campbell ' s Urology. Philadelphia: Saunders Company. 2002. 1297-1330.
  • 4Dahle SE,Chokkalingam AP, Gao YT, et al. Body size and serum level of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol, 2002, 168:599-604.
  • 5Kasturi S, Russell S, Mcvary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Prostate Rep, 2006,4: 127-131.
  • 6Parsons JK,Carter HB,Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab ’ 2006,91: 2562-2568.
  • 7Vikram A, Jena GB,Ramarao P. Increased cell proliferation and contract-ility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate, 2010, 70 :79-89.
  • 8Libby G,Donnelly LA, Donnan PT,et al. New users of metformin are at low risk of incident cancer : a cohort study among people with type 2 diabetes. Diabetes Care, 2009,32 : 1620-1625.
  • 9Bodmer M, Meier C,Krahenbuhl S, et al. Longterm metformin use is associated with decreased risk of breast cancer. Diabetes Care, 2010, 33: 1304-1308.
  • 10Landman GW,Kleefstra N, Van Haleren KJ,et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 2010, 33:322-326.

共引文献29

同被引文献106

  • 1万少平,胡礼泉,刘源,田斌群,李世文.成年男性下尿路症状与尿流率和前列腺体积的相关性研究[J].武汉大学学报(医学版),2004,25(6):702-704. 被引量:12
  • 2郭艺芳,姚丽霞,刘坤申.人体血压的昼夜节律:杓型与非杓型血压的临床意义[J].心血管病学进展,2005,26(1):11-13. 被引量:45
  • 3Griebling T. Prevalence and correlates of nocturia in communitydwelling older men: results from the korean longitudinal study on heahh and aging [ J ]. J Urul, 2013,189 ( 6 ) : 2208-2209. DOI : 10. 1016/j. juro. 2013.03. 013.
  • 4Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment [ J]. Postgrad Med, 2015, 127 ( 3 ) : 301-307. DOI: 10. 1080/00325481. 2015. 1018799.
  • 5Lin J, Zhou J, Xu W, et al. Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STA33 signaling pathway[J]. ExpTher Med, 2013,5(5) :1293-1300. DOI: 10. 3892/etm. 2013. 1008.
  • 6Stroup SP, Palazzi-Churas K, Kopp RP, et al. Trends in adverse events of benign prostatic: hyperplasia (BPH) in the USA, 1998 to 2008[J]. BJU lnt ,2012,109(1):84-87. DOI: 10. 1111/j. 1464-410X. 2011.
  • 7Kaplan SA. Ursollc acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia [ J ]. J Urol,2013 ,89( 1 ) :388. DOI: 10. 1016/j. juro. 2012.09. 143.
  • 8Titus MA, Li Y, Kozyreva OG, et al. 5ct-reductase type 3 enzyme in benign and malignant prostate [J]. Prostate ,2014,74 ( 3 ) :235- 249. DOI: 10. 1002/pros. 22745.
  • 9Osman NI, Chapple CR, Cruz F, et al. Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia[J]. Expert Opin Pharmacother ,2012,13 (14) : 2085-2096. DOI : 10. 1517/ 14656566. 2012. 714368.
  • 10Levakov AF, Kaeanski MM, Vuckovie N, et al. The expression and localization of estrogen receptor beta in hyperplastic and neo- plastic prostate lesions. [ J ]. Vojnosanit Pregl, 2015,72 ( 10 ) : 906-913. DOI: 10.2298/VSP131022069F.

引证文献10

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部